An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-Tandem mass spectrometry

Analytical and Bioanalytical Chemistry

Volumn 403, Issue 6, 2012, Pages 1685-1695

  Couchman, L ^a   Birch, M ^a   Ireland, R ^b   Corrigan, A ^c   Wickramasinghe, S ^c   Josephs, D ^d   Spicer, J ^d   Flanagan, R J ^a  

^a Northern Care Alliance NHS Foundation Trust   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Automated sample preparation; Dasatinib; Imatinib; Nilotinib; TDM; TKIs; TurboFlowMS MS

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; SAMPLE PREPARATION; TKIS; TURBOFLOWMS/MS;

ACETONITRILE; AMINO ACIDS; BODY FLUIDS; CENTRIFUGATION; DRUG INTERACTIONS; ENZYMES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PATIENT MONITORING; PATIENT TREATMENT; PLASMA (HUMAN); STORMS; TIME DIVISION MULTIPLEXING;

AUTOMATION;

PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; AUTOMATION; BLOOD; CALIBRATION; DRUG ANTAGONISM; HUMAN; LIQUID CHROMATOGRAPHY; METHODOLOGY; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

AUTOMATION; CALIBRATION; CHROMATOGRAPHY, LIQUID; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

ARIA;

EID: 84861231146     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-5970-2     Document Type: Article

References (26)

1. Kolibaba KS, Druker BJ (1997) Protein tyrosine kinases and cancer. Biochim Biophys Acta 1333:F217-F248 (Pubitemid 28015315)
2. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502
3. BNF (2011) British national formulary, edition 62. BMJ Group/Pharmaceutical Press, London
4. Van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Rev 35:692-706
5. Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: Focus on 4-Anilinoquinazolines. Clin Pharmacokinet 50:371-403
6. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: Focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50:551-603
7. Titier K, Picard S, Ducint D, Teilhet E, Moore N, Berthaud P, Mahon FX, Molimard M (2005) Quantification of imatinib in human plasma by high-performance liquid chromatographytandem mass spectrometry. Ther Drug Monit 27:634-640 (Pubitemid 41437643)
8. Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98:1633-1640 (Pubitemid 351684684)
9. Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N, Decosterd LA (2009) Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:1982-1996
10. Faber E, Friedecký D, Micová K, Divoká M, Katrincsáková B, Rožmanová S, Jarošová M, Indrák K, Adam T (2010) Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response. Int J Hematol 91:897-902
11. Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, Titier K, Molimard M (2011) Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 412:1060-1067
12. Buclin T, Widmer N, Biollaz J, Decosterd LA (2011) Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. Lancet Oncol 12:9-11
13. Faber E, FriedeckýD, Micová K, Rožmanová S, DivokáM, Jarošová M, Indrák K, Adam T (2012) Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Ann Hematol (in press)
14. Chassaing C, Stafford H, Luckwell J, Wright A, Edgington A (2005) A parallel micro turbulent flow chromatography-Tandem mass spectrometry method for the anlaysis of a pharmaceutical compound in plasma. Chromatographia 62:17-24 (Pubitemid 41124586)
15. Breaud AR, Harlan R, Di Bussolo JM, McMillin G, Clarke W (2010) A rapid and fully-Automated method for the quantitation of tricyclic antidepressants in serum using turbulent-flow liquid chromatography-Tandem mass spectrometry. Clin Chim Acta 411:825-832
16. Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F, Tod M (2009) Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta 404:134-139
17. Chahbouni A, Den Burger JCG, Vos RM, Sinjewel A, Wilhelm AJ (2009) Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry. Ther Drug Monit 31:683-687
18. Honeywell R, Yarzadah K, Giovannetti E, Losekoot N, Smit EF, Walraven M, Lind JSW, Tibaldi C, Verheul HM, Peters GJ (2010) Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:1059-1068
19. Roche S, McMahon G, Clynes M, O'Connor R (2009) Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. J Chromatogr B Analyt Technol Biomed Life Sci 877:3982-3990
20. FDA/CDER (Food and Drug Administration/Center for Drug Evaluation and Research) (2001) Guidance for industry. Bioanalytical method validation (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070107.pdf. Accessed 6 January 2012)
21. Peters FT, Drummer OH, Musshoff F (2007) Validation of new methods. Forensic Sci Int 165:216-224 (Pubitemid 46073540)
22. Bonfiglio R, King RC, Olah TV, Merkle K (1999) The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom 13:1175-1185 (Pubitemid 29285118)
23. Edge T (2003) Turbulent flow chromatography in bioanalysis. In: Handbook of analytical separations, vol 4. Elsevier, Amsterdam, pp 91-128
24. Swaisland HC, Cantarini MV, Fuhr R, Holt A (2006) Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 45:633-644 (Pubitemid 44046489)
25. Medina PJ, Goodin S (2008) Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Therapeutics 30:1426-1447
26. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega A, Massinimi G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35 (Pubitemid 46630490)